

Supplementary Table 5 4EBP1 and p4EBP1_S65 protein in the Stockholm 3 cohort: correlations to clinicopathological factors and the AKT/mTOR pathway.

4EBP1 cytoplasm	Spearman R	p-value	4EBP1 nucleus	Spearman R	p-value
<i>Tamoxifen treatment</i>	-0.01	0.82	<i>Tamoxifen treatment</i>	0.00	0.98
<i>Tumour size > 20mm</i>	0.11	0.0037	<i>Tumour size > 20mm</i>	0.04	0.29
<i>Nottingham grade</i>	0.22	<0.0000001	<i>Nottingham grade</i>	0.07	0.09
<i>ER</i>	-0.13	0.0006	<i>ER</i>	-0.03	0.48
<i>PgR</i>	-0.07	0.082	<i>PgR</i>	0.01	0.75
<i>HER2</i>	0.13	0.00096	<i>HER2</i>	0.04	0.33
<i>pAKTcyt</i>	0.20	<0.0000001	<i>pAKTn</i>	0.01	0.74
<i>pmTORcyt</i>	0.02	0.61	<i>pmTORn</i>	N/A	
<i>S6K2cyt</i>	0.20	<0.0000001	<i>S6K2n</i>	0.05	0.21
<i>p4EBP1_S65 cyt</i>	0.39	<0.0000001	<i>p4EBP1_s65 n</i>	0.14	0.00028

p4EBP1_S65 cytoplasm	Spearman R	p-value	p4EBP1_S65 nucleus	Spearman R	p-value
<i>Tamoxifen treatment</i>	-0.04	0.29	<i>Tamoxifen treatment</i>	-0.05	0.15
<i>Tumour size > 20mm</i>	0.09	0.015	<i>Tumour size > 20mm</i>	-0.11	0.0033
<i>Nottingham grade</i>	0.34	<0.0000001	<i>Nottingham grade</i>	-0.08	0.044
<i>ER</i>	-0.16	0.0000009	<i>ER</i>	0.03	0.4
<i>PgR</i>	-0.08	0.027	<i>PgR</i>	0.04	0.33
<i>HER2</i>	0.11	0.0046	<i>HER2</i>	-0.09	0.022
<i>pAKTcyt</i>	0.34	<0.0000001	<i>pAKTn</i>	0.22	<0.0000001
<i>pmTORcyt</i>	0.00	0.92	<i>pmTORn</i>	N/A	
<i>S6K2cyt</i>	0.14	0.0001	<i>S6K2n</i>	0.17	0.000002
<i>4EBP1cyt</i>	0.39	<0.0000001	<i>4EBP1n</i>	0.14	0.00028

